Market Cap 164.8B
Revenue (FYR) $62.5B
EPS (TTM) $4.87
Shares Out. 2.7B
Book Value $20.85
Dividend Yield 3.60%
Div/Share $2.16
P/E 12.3x
Price/Sales (FYR) 2.6
P/Cash Flow (TTM) 10.0x
Johnson & Johnson
is a profitable Major Drugs company JNJ is engaged in the
research and development, manufacture and sale of a range of
products in the healthcare field. Johnson & Johnson has more
than 250 operating companies.
The Company operates in three
segments. The Consumer segment includes a range of products
used in the baby care, skin care, oral care, wound care and
women's healthcare fields, as well as nutritional and
over-the-counter pharmaceutical products.
The Pharmaceutical
segment includes products in the therapeutic areas, such as
anti-infective, antipsychotic, cardiovascular,
contraceptive, dermatology, gastrointestinal, hematology,
immunology, neurology, oncology, pain management, urology
and virology.
The Medical Devices and Diagnostics segment
includes a range of products distributed to wholesalers,
hospitals and retailers. In July 2009, Johnson & Johnson
completed the acquisition of Cougar Biotechnology, Inc. with
approximately 95.9% interest in Cougar Biotechnology's
outstanding common stock.
Terms
Of Use
By using this site,
you agree to be bound by its terms of use.
The full terms of
use can be read here.
If you do not agree to the terms of use, do not access or use
this site.
Nothing presented is financial advice, trading advice or
recommendations. Everything presented is the author's ideas
only. The author accepts no liability for its use including
errors and omissions. You alone are solely responsible for your
own investing and trading. There are considerable risks involved
in implementing any investment strategies and losses can be
large. Trade at your own risk.
JOHNSON &
JOHNSON (JNJ) - 2011
ONGOING EVALUATION
& TRADE
The
current strategy is selling naked puts near and at the money until I either accept
assignment OR get assigned shares. Then I will turn to
covered calls. Should the stock fall too low making
covered call selling impractical I will add to my stock
position through selling naked puts to lower my overall
cost.
Should you find my strategy and ongoing evaluation of
this trade of value I hope you will consider a tip
for the time I spend detailing out this trade.
I have set up a Paypal account for those
who would like to donate. Thank you in advance. Remember, nothing on my site is financial advice.
They are just my ideas and opinions. Investing is risky and losses can be large. Trade
at your own risk.
Read the
terms of use
YEAR 1: 2009 - Trade Commenced Feb 26 2009 Goal for 2009:
8.5% (10 months)
Strategy: Sell Naked Puts Until Assigned
Capital In Use At End Of 2009
53,500.00
Income Earned in 2009 (10 months)
4276.00
Return On Capital in 2009 (5 months)
7.9%
YEAR 2: 2010 Goal for 2010: 10%
Strategy: Sell Naked Puts Until Assigned
Capital In Use At End
Of 2010
81,000.00
Income Earned in 2010
7960.75
Return On Capital For
2010
9.8%
YEAR 3: 2011 Goal for 2011: 12%
Strategy: Sell Naked Puts Until Assigned
Capital Currently In Use
82295.50
Income Earned in 2011
4893.50
TOTAL INCOME EARNED
TO DATE
17130.25
Total Of My Own Capital
Required
65165.25
Number Of Shares if
assigned
1400
Share Price Valuation
(Total Capital Required/Number of shares)
46.55
TRADE COMMENCED: Feb 26
2009 * ACTIVE TRADES ARE HIGHLIGHTED
IN YELLOW
Dec 17 10
62.54
STO 2 NP JAN 2012 60.00 @ 4.60
7.6
9.50
12009.50
910.50
11921.75
Dec 31 10
61.85
BTC 2 NP JAN
$65.00 @ 3.10
4.7
9.50
(629.50)
11292.25
Dec 31 10
61.85
STO 2 NP FEB $65.00 @ 3.55
COMMENTS: This is a roll from Jan to Feb to continue
bringing in more premium. I would not roll out further, in
case the stock should move higher which would decrease the
premium in the Feb put and increase premiums should I roll
further out in time.
Expiry: BTC 2 NP FEB $65.00 @ $4.15
4 Naked Puts Feb $60 expired
(6.3%)
9.50
(839.50)
12025.75
Feb
22 11
60.90
STO
2 NP 16JUL11 $65.00 @ $4.95
7.6%
9.50
980.50
13006.25
Feb
28 11
61.30
BTC
4 NP 19MAR11 $62.50 @ 1.72
COMMENTS: With today's upturn I closed my Mar $62.50 naked
puts. I then reduced the number of puts to 2 and moved to
April $62.50 and held 2 back.
(2.7%)
12.00
(700.00)
12306.25
Mar
2 11
60.50
STO
2 NP 16APR11 $62.50 @ 2.65
4.2%
9.50
520.50
12826.75
Mar
16 11
57.70
STO
2 NP 16JUL11 $57.50 @ 2.87
COMMENTS: I have taken advantage of today's downturn to sell
out to July, the other two naked puts but at $57.50 which
covers the entire cost of the buy back of the Mar $62.50 and
leaves me with a further profit.
5.0%
9.50
564.50
13391.25
Mar
18 11
58.60
BTC
3 NP 16APR11 $65.00 @ 6.50
I took advantage of today's upturn to buy back my Apr $65.00
puts. I then have rolled out two of them to Jan to reduce my
overall cost on the puts.
STO
2 NP 21JAN12 $65.00 @ 9.05 (Bought back on Nov 29 11 for
$2.85)
13.9%
9.50
13009.50
1800.50
13231.00
Mar 18 2011:
I received a lot of emails this week from concerned
investors as JNJ pulled back. The recent downturn in Johnson
and Johnson does not concern me. In fact it is an
opportunity.
Read here the importance of having a
plan when investing in a stock, including Johnson
and Johnson stock.
